Pharmaterials, a UK-based early phase pharmaceutical development company, has officially opened the doors to its new facility in Reading.
The dedicated 30,000 sq ft facility has been fitted out to meet the specific needs of the business and the requirements of GMP manufacture for early phase clinical trials, with specific expertise in inhalation and oral dose forms. The facility currently has three non-sterile manufacturing rooms controlled to Grade D, suitable for the manufacturing of oral dosage forms and inhalation products.
Pharmaterials provides solutions to poorly soluble drug formulation and inhaled drug delivery and can provide material for studies for early phase clinical studies. With expertise in pharmaceutical materials science, salt selection, polymorphism, amorphous materials, and preclinical formulation, the move to clinical formulation and GMP now allows Pharmaterials to provide a "Fast to Man" development service under one roof.
Professor Graham Buckton, ceo of Pharmaterials, said: "Our investment in new facilities and state-of-the-art equipment will allow the true potential of our team to be realised. Pharmaterials will be positioned to take our customers new molecules in to the clinic in the shortest possible time, meeting the pressures of today's drug development".
The company was acquired by PII, a US-based contract formulation and manufacturing company, in January 2008. Located in Baltimore, PII is able to manufacture solid oral, semi-solid and liquid dosage forms (tablets, hard and soft gelatine capsules, pellets sustained release products etc as well as aseptic vial filling.